Gliomas are the most common central nervous system (CNS) neoplasms in childhood, accounting for 35% of pediatric CNS tumors [
1]. They encompass a wide range of entities (including astrocytic and mixed neuronal-glial tumors), exhibiting different growth patterns (from diffuse to circumscribed) and comprising both high- and low-grade malignancies [
1]. Gliomas present different characteristics between pediatric and adult age, such as genetic mutations and response to therapy [
2]. In the assessment of pediatric brain gliomas, PET imaging employing amino acid radionuclides has demonstrated the ability to address limitations of (i) conventional magnetic resonance imaging (MRI) [
2], and (ii) the restricted contrast associated with the use of the radiopharmaceutical 18F-fluorodeoxyglucose ([
18F]-FDG) in neuro-oncology [
3,
4]. Furthermore, 18F-labeled tracers are becoming more prevalent due to their extended half-life, conversely to 11C tracers [
5]. Among these radionuclides, 18F-dihydroxyphenylalanine (DOPA) has emerged as particularly notable because its uptake significantly correlates with tumor grading [
6] and prognosis [
7] in patients with infiltrating gliomas. Additionally, [
18F]F-DOPA PET demonstrated a potential role to non-invasively determine the H3K27M mutation status in diffuse midline gliomas (DMG), such as diffuse intrinsic pontine gliomas (DIPG), which are malignant brainstem gliomas where biopsy is not routinely performed since diagnosis can still be made based on clinical and imaging features alone [
8,
9,
10]. In clinical practice, [
18F]F-DOPA PET analysis of pediatric gliomas is based on standard parameters such as tumor-to-striatum (T/S) and tumor-to-background tissue (T/N) ratios. However, these parameters may show limitations for certain lesion types, and in recent years, the use of dynamic parameters (i.e., the shape of the time activity curve and the steepness of the uptake curve) has increased to overcome these limitations [
10,
11]. Of note, In 2022 Fiz et al [
12] conducted a pioneering study of static and dynamic [
18F]F-DOPA PET parameters in 15 children with brain gliomas. They highlighted the correlation of the T/S ratio with outcomes and observed that time-activity curve (TAC) patterns best correlated with OS and progression-free survival (PFS). Two distinct patterns were identified: an accumule trend in low-grade neoplasms and a plateau pattern in aggressive gliomas, consistent with the guidelines in [
13]. Despite these significant research advancements, highlighting the diagnostic and prognostic value of [
18F]F-DOPA PET-derived parameters, clinical practice still faces challenges in accurately and reproducibly measuring these markers. Nuclear medicine physicians typically measure quantitative markers from PET scans with limited computer assistance. For instance, they delineate a circular ROI centered on the maximum tumor and striatum uptake to compute maximum T/S. When the lesion uptake resembles that of healthy brain tissue, clinicians manually place a ROI on the area of signal abnormality in the T2-weighted MRI scan and transfer it to the co-registered PET scan. The normal uptake region (N) is traditionally delineated by positioning a sphere on the contralateral semi-oval center, including gray and white matter [
14,
15]. This approach is also applied to TAC extraction, where segmentation is particularly challenging due to the limited anatomical information within the dynamic PET scans. This working method is time consuming and has low reproducibility, so it is essential to define an automatic workflow that is less dependent on the manual definition of ROI or VOI. Our work aims to implement a semi-automated image processing framework for [
18F]F-DOPA PET, integrating it into the clinical workflow of neuro-oncology. This pipeline is designed to extract both static and dynamic parameters to support nuclear medicine specialists in assessing pediatric brain tumors by accelerating analysis time and improving the accuracy of PET-derived parameters to overcome the inherent drawbacks of manual analysis.